期刊文献+

反相高效液相色谱法测定伏立诺他含量和有关物质 被引量:1

Determination of vorinostat and its related substances by RP-HPLC
原文传递
导出
摘要 目的:建立伏立诺他含量及有关物质的反相高效液相色谱测定方法。方法:采用Kromasil C18色谱柱(250 mm×4.6 mm,5μm);含量测定以0.1%磷酸溶液(三乙胺调节pH值至3.0)-乙腈(70∶30)为流动相,有关物质采用梯度洗脱;流速为1 mL.min-1;检测波长为241 nm。结果:伏立诺他与各杂质之间均达到良好分离,伏立诺他在5.3~266μg.mL-1范围内呈良好的线性关系(r=1),其最低检测限为0.3 ng(S/N=3)。结论:该方法简便、准确、可靠,适用于伏立诺他的质量控制。 Objective: To establish an RP-HPLC method for determination of vorinostat and its related substances.Methods: A Kromasil-C18 column(250 mm×4.6 mm,5 μm) was used and the mobile phase was 0.1% H3PO4(pH 3.0 adjusted by triethanolamine)-acetonitrile(70∶30) for determination of vorinostat.Gradient elution was programmed for detecting related substances.The flow rate was 1.0 mL·min-1 and the detection wavelength was 241 nm.Results: Vorinostat was completely separated from the 5 known impurities.The linear range of vorinostat was 5.3~266 μg·mL-1(r=1) and the limit of detection was 0.3 ng(S/N=3).Conclusion: The method is simple,accurate and reliable for the quality control of vorinostat.
出处 《中国新药杂志》 CAS CSCD 北大核心 2011年第24期2467-2470,共4页 Chinese Journal of New Drugs
关键词 伏立诺他 反相高效液相色谱法 含量测定 有关物质 vorinostat RP-HPLC content determination related substances
  • 相关文献

参考文献11

  • 1杨梅.皮肤T细胞淋巴瘤治疗新药伏立诺他[J].中国新药杂志,2010,19(8):646-649. 被引量:10
  • 2黄小平,徐江.组蛋白去乙酰化酶抑制剂类抗癌药Vorinostat[J].化工中间体,2009,5(6):11-14. 被引量:3
  • 3张兴锴,孙铁民.治疗皮肤癌新药vorinostat[J].中国药物化学杂志,2007,17(4):268-268. 被引量:10
  • 4HEYMANN WR. Treatment of cutaneous T-cell lymphoma:focus on vorinostat [ J ], J Am Acad Dermatol,2008,59 ( 4 ) :696 - 697.
  • 5RICHON VM, GARCIA-VARGAS J,HARDWICK JS. Development of vorinostat : current applications and future perspectives for cancer therapy [ J ]. Cancer Lett,2009. 280 (2) :201 - 210.
  • 6吕俊玲,封宇飞,傅得兴.组织蛋白去乙酰化酶抑制剂伏瑞斯特的药理与临床[J].中国新药杂志,2009,18(3):187-189. 被引量:1
  • 7KAVANAUGH SM, WHITE LA, KOLESAR JM. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma[J].Am J Health Syst Pharm,2010,67( 10) :793-797.
  • 8GARDNER JM, EVANS KG, GOLDSTEIN S,et al. Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma[J]. Arch Dermatol,2009, 145 (9) :985 -988.
  • 9DUVIC M,OLSEN EA, BRENEMAN D,et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma[J]. Clin Lymphoma Myeloma,2009,9(6) :412 -416.
  • 10ROBERT AP, JULIANNE LH,JAN HB. A liquid chromatogra- phy-eleetrospray ionization tandem mass spectrometric assay for quantitation of the histone deaeetylase inhibitor,vorinostat ( sube- roylanilide hydroxamicacid, SAHA), and its metabolites in human serum [ J ]. J Chromatogr B Analyt Technol Biomed Life Sei, 2006,840(2) :108 - 115.

二级参考文献32

  • 1李晓晖,李建勋,李世荣,修志龙,西野宪和.环肽类组蛋白去乙酰化酶抑制剂[J].化学进展,2007,19(5):762-768. 被引量:7
  • 2THOMPSON CA. Vorinostat approved for rare lymphoma[J].Am J Health Syst Pharm, 2006, 63(22) :2168.
  • 3DUVIC M, VU J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma [ J ]. Expert Opin Investig Drugs, 2007,16 ( 7 ) : 1111 - 1120.
  • 4Vorinostat. [ EB/OL]. (2007 - 12 - 04 ). http ://www. fda. gov/ cder/foi/label/2006/0219911bl. pdf.
  • 5RUBIN EH, AGRAWAL NG, FRIEDMAN EJ,et al. A sludy to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer[J].Clin Cancer Res, 2006,12 (23) :7039 - 7045.
  • 6KELLY WK, O'CONNOR OA, KRUG LM, et al. Phase 1 study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer[ J ]. J Clin Oncol, 2005, 23(17) :3923 -3931.
  • 7MANN BS, JOHNSON JR, COHEN MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma[ J ]. Oncologist, 2007,12 ( 10 ) : 1247 - 1252.
  • 8OLSEN EA, KIM YH, KUZEL TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma [ J ]. J Clin Oneol, 2007,25(21) :3109 -3115.
  • 9DUVIC M, TALPUR R, NI X, et al. Phase 2 trial of oral vorinostat ( suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma(CTCL) [J]. Blood, 2007, 109(1) :31 -39.
  • 10CRISCIONE VD, WEINSTOCK MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973 -2002 [ J]. Arch Dermatol, 2007,143 (7) :854 - 859.

共引文献17

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部